IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy
Berlin, Germany, and Research Triangle Park, N.C., USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaRegenerative Medicine ...
Multiple System Atrophy Market Set to Experience Significant Growth with Breakthrough Therapies by 2034 | DelveInsight
Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...
Parkinson's Disease Treatment Market To Worth USD 3.71 Billion By 2032 SNS Insider
Parkinson's Disease Treatment Market Aging Populations and Advancements in Deep Brain Stimulation, Gene Therapy, and Medications Fuel Marke ...
IRLAB Therapeutics: IRLAB Publishes Full-Year Report for 2024
GOTHENBURG, SE / ACCESS Newswire / February 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 12, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company d ...
newtonnews11d
Revolutionary Parkinson’s Treatment
A County Durham resident has become one of the first patients in England to benefit from a groundbreaking new treatment for ...
Pharm Exec13d
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...
Medscape13d
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
MedPage Today14d
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by ...